Abstract 1710P
Background
The COVID-19 pandemic has dramatically changed the Health Care System organization in many European countries. Many Oncology departments have rapidly implemented telehealth in their clinical practice. For breast cancer (BC) patients (pts), up to 80% of all in-person visits have been transformed in TV.
Methods
18 centers from France and Italy invited all BC pts who have had at least one TV (Visio conference or telephone) during the COVID-19 pandemic to answer an online, anonym questionnaire (Q) ontheir experience with TV. Q included 42 questions: demographic data, BC medical situation, TSQ scale (telehealth specific Q), physician’s module of EORTC OUTPATSAT35 (11 SAT35), and HADS anxiety scale. The primary objective was to evaluate satisfaction with TV. Secondary objectives: anxiety, factors associated with satisfaction and description of satisfaction in pts’ subgroups.
Results
Between 6/4/2020 and 15/05/2020, 1244 pts (out of 3762 invited) filled in the Q and were included in the analysis. Main characteristics and results are shown in the Table. Mean 11 SAT35: 85.21 and 77.41 for pts who had visio versus telephone TVs respectively. 11 SAT35 was highly correlated to HADS score (p < 0.001). Multivariate analyses will be presented. Table: 1710P
| All | Ong. trt for localized BC | Ong. trt for metastatic BC | Surveillance | |
| N | 1244 | 204 | 302 | 641 |
| Mode of TV Visio Telephone | 132 (10.6%) 1112 (89.4%) | 32 (15.7%) 172 (84.3%) | 22 (7.3%) 280 (92.7%) | 62 (9.7%) 579 (90.3%) |
| Mean TSQ score (/75) (N = 1165) | 55.24 (+/-11.49) | 56.41 (+/-10.99) | 56.61 (+/-10.93) | 53.87 (+/-11.86) |
| Mean 11 SAT35 score (/100) (N = 1166) | 78.23 (+/-16.67) | 79.01 (+/- 16.14) | 79.03 (+/- 16.37) | 77.6 (+/- 17.04) |
| Globally satisfied (%) (N = 1166) | 90.5 | 92.9 | 92.6 | 88.3 |
| Mean HADS score (+/-sd) (N = 1150) | 7.34 (+/- 4.07) | 7.68 (+/- 3.88) | 7.52 (+/- 4.22) | 7.14 (+/- 4.05) |
| Would like to have routine TVs (%) (N = 1132) | 59.2 | 62.8 | 63.0 | 54.7 |
Conclusions
TV during the COVID-pandemic appeared feasible and well accepted by BC pts regardless of their medical situation and mode of TV. Anxiety was high during this period, and correlated with satisfaction. These findings help identifying BC pts who may be proposed TV beyond the pandemic crisis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Levy: Honoraria (self): Pfizer; Honoraria (self), Travel/Accommodation/Expenses: Roche; Honoraria (self): MSD; Honoraria (self), Travel/Accommodation/Expenses: Lilly; Travel/Accommodation/Expenses: Daiichi. C. Uzan: Honoraria (self), Advisory/Consultancy: Roche. D. Genet: Advisory/Consultancy: AstraZeneca; Travel/Accommodation/Expenses: Roche; Amgen; Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis. A. Patsouris: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: ESAI; Travel/Accommodation/Expenses: Pfizer; Honoraria (institution): Lily; Research grant/Funding (institution): ESAI. V.C. Dieras: Advisory/Consultancy, Travel/Accommodation/Expenses, and travel expenses and speaker: Roche; Novartis; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses, and travel expenses and speaker: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses, and travel expenses and speaker: Lilly; AstraZeneca; Daiichi Sankyo; Advisory/Consultancy: Abbvie; MSD; Eisai. Speaker Bureau/Expert testimony: Seattle Genetics. J-Y. Pierga:Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Roche; Honoraria (self), Speaker Bureau/Expert testimony: Ipsen; Novartis; AstraZeneca; Amgen. S. Ladoire: Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony, and Travel/Accommodation expense: Pfizer; BMS; Ipsen; Janssen Oncology; Sanofi; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: Astellas Pharma. W. Jacot: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Eisai; Lilly France; Pfizer; Roche; Honoraria (self): MSD; Travel/Accommodation/Expenses: Novartis; Sanofi Aventis; GSK; Fabre; Chugai Pharma. S. Delaloge: Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Roche; Pfizer; Honoraria (institution), Research grant/Funding (institution): Sanofi; BMS;Honoraria (institution): Pierre Fabre; Puma; Lilly; Servier; Research grant/Funding (institution): Orion; MSD; Daichy. M. Lambertini: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: Takeda; Lilly; Theramex. B. Pistilli: Advisory/Consultancy: PUMA biotechnologies; Speaker Bureau/Expert testimony: Fabre; Novartis; Myriad genetics; Travel/Accommodation/Expenses: MSD oncology; Astra Zeneca; Novartis; Pfizer. All other authors have declared no conflicts of interest.